Company News
Contineum Stock Falls 8% on Phase‑2 Miss
Contineum Therapeutics Inc. shares dropped 8% in after‑hours trading on Monday after its phase‑2 MOONLIGHT‑1 trial missed the primary efficacy endpoint.
The trial, evaluating JNJ‑5120/PIPE‑307 in majo
